WHAT IS BORRELIA BURGDORFERI C6 PEPTIDE ANTIBODY TEST?

WHAT IS BORRELIA BURGDORFERI C6 PEPTIDE ANTIBODY TEST?

See Lyme disease antibody—Blood for a description of Lyme disease. This blood test identifies the C6 glycoprotein, a newly discovered peptide, which is part of the variable antigen VlsE1,2. C6 is important because it can definitively confirm active infection with Borrelia burgdorferi, the causative agent of Lyme disease, even in those who have previously had the disease or been vaccinated for it. In this group of people, the active disease could be present, but traditional IgG and IgM antibody testing could indicate immunity. This is because the antibodies can remain present for up to 20 years after the acute disease resolves in those who previously had Lyme disease, yet the person can become reinfected. In addition, 25% of people vaccinated for Lyme disease fail to develop enough OpsA antibodies for active immunity. It is the OpsA antibodies that cause the false-positive results on traditional tests. Because the C6 peptide does not target OpsA antibodies for measurement, it is ideal for definitive testing. 

 

KNOWLEDGE BASE
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

X